Has Riem Badr, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,475 in general payments to Riem Badr, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Riem Badr, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Riem Badr, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Riem Badr, MD

Hematology · Port Jefferson Station, NYNPI 1649571407

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,788 of the $12,475 with a category attached, or 78.5%. Roche Diagnostics Corporation accounts for 95.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $11,968 and has fallen 97.7% since, to $272 in 2025.

$12,475in general payments, 2019–2025

Across 16 payments — averaging $779.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Roche Diagnostics Corporation$12K
Caris MPI, Inc.$187
Novartis$125
Abbott$85
Jazz Pharmaceuticals Inc.$50
AstraZeneca$44
plus $16 from 1 others

What the payments were for

Speaking & faculty fees$9,78878%
Travel & lodging$2,00316%
Food & beverage$6845%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Roche Diagnostics Corporation	7	$11,968
Caris MPI, Inc.	4	$187
Novartis	1	$125
Abbott	1	$85
Jazz Pharmaceuticals Inc.	1	$50
AstraZeneca	1	$44
Amgen	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,475 in reported general payments places this provider in the 80th percentile of 157 hematology providers in New York.

See all hematology providers in New York →

Medicare billing

Part B allowed, 2024

$7,933,863

Medicare patients

11,617

Services billed

185,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Port Jefferson Station

Barry CollerNew York$7.9M
Allyson OceanNew York$1.4M
Ahmed SawasNew York$618K
Jeffrey ZwickerNew York$561K
Dan DouerNew York$477K
Ran ReshefNew York$468K
Faith DaviesNew York$307K
Michael MauroNew York$229K
Richard FurmanNew York$208K
Ann JakubowskiNew York$123K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →